我是 LongbridgeAI，我可以總結文章信息。Sandoz 集團宣佈將在特朗普總統提議自 2028 年 8 月起對仿製藥徵收 100% 關税後，與美國政策制定者進行接觸。這家瑞士製造商表示，目前評估該措施對其運營或投資的影響為時尚早，並指出需要進一步瞭解該措施的範圍。Sandoz 強調其致力於改善美國藥品的可負擔性和可及性，並表示願意與官員對話，以實現這些共同目標
By Adria Calatayud
Sandoz Group said it would engage with U.S. policymakers after President Trump announced a 100% tariff on generic drugs from 2028, but that it is too early to assess how the plan will affect its manufacturing or investments.
Trump posted on social media Tuesday that he would give manufacturers of generic drugs time to move facilities to the U.S. before putting in place a 100% tariff starting in August 2028.
In response, Swiss generic-drug maker Sandoz said Wednesday that further details on the scope and implementation of the measure are still required before it can assess its potential implications.
"We share the goal of improving affordability and access to medicines in the United States," a Sandoz spokesman said. "We look forward to continuing our dialogue with policymakers on how best to achieve these shared objectives."
The company said generics and biosimilars--copycat biologic drugs--already contribute to lowering healthcare costs and broaden access to treatment for patients.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 22, 2026 02:02 ET (06:02 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.